$58.79

+0.79 (+1.36%)

OTC · Healthcare · Medical - Pharmaceuticals · Tech Score Buy · Power 66 · $12.0B mcap · 99M float · 0.0000% daily turnover · Short 96% of daily vol

Revenue

$2.3B +12.4% ▲

5Y CAGR: +9.6%

Gross Profit

$1.6B +8.0% ▲

5Y CAGR: +8.9%

Operating Income

$639M +14.5% ▲

5Y CAGR: +6.5%

Net Income

$417M +7.0% ▲

5Y CAGR: +2.5%

EPS (Diluted)

$1.99 +7.0% ▲

5Y CAGR: +2.5%

EBITDA

$796M +12.3% ▲

5Y CAGR: +8.2%

View Full Income Statement

Line Item	FY2020	FY2021	FY2022	FY2023	FY2024
Revenue	$1.4B	$1.6B	$1.9B	$2.1B	$2.3B
YoY Growth	-2.2%	+9.1%	+17.3%	+12.4%	+12.4%
Cost of Revenue	$407M	$428M	$567M	$601M	$741M
Gross Profit	$1.0B	$1.2B	$1.3B	$1.5B	$1.6B
Gross Margin	71.9%	72.9%	69.4%	71.1%	68.3%
R&D Expenses	$146M	$166M	$220M	$256M	$286M
SG&A Expenses	$422M	$481M	$572M	$601M	$654M
Operating Expenses	$568M	$647M	$792M	$924M	$961M
Operating Income	$469M	$490M	$437M	$558M	$639M
Operating Margin	32.4%	31.0%	23.6%	26.8%	27.3%
Interest Expense	$17M	$21M	$34M	$75M	$82M
Income Before Tax	$456M	$463M	$401M	$491M	$547M
Tax Expense	$101M	$77M	$89M	$102M	$131M
Net Income	$355M	$386M	$312M	$389M	$417M
Net Margin	24.5%	24.4%	16.9%	18.7%	17.8%
EPS (Diluted)	$1.70	$1.85	$1.49	$1.86	$1.99
EBITDA	$567M	$578M	$559M	$709M	$796M
Shares Outstanding	209M	209M	209M	209M	209M

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$557M	$598M	$680M	$644M	$632M	$662M	$716M	$696M
Cost of Revenue	$172M	$185M	$221M	$220M	$200M	$190M	$203M	$199M
Gross Profit	$385M	$413M	$459M	$424M	$432M	$473M	$513M	$497M
Gross Margin	69.1%	69.1%	67.5%	65.8%	68.4%	71.4%	71.6%	71.4%
R&D Expenses	$66M	$81M	$80M	$87M	$80M	$94M	$87M	$93M
SG&A Expenses	$149M	$184M	$181M	$187M	$171M	$187M	$193M	$201M
Operating Expenses	$220M	$279M	$263M	$289M	$267M	$250M	$280M	$294M
Operating Income	$166M	$135M	$196M	$135M	$166M	$223M	$233M	$203M
Operating Margin	29.7%	22.5%	28.8%	21.0%	26.2%	33.7%	32.5%	29.2%
Interest Expense	$19M	$22M	$26M	$24M	$23M	$25M	$29M	$24M
Income Before Tax	$150M	$105M	$165M	$119M	$145M	$152M	$202M	$161M
Tax Expense	$37M	$27M	$40M	$28M	$35M	$35M	$48M	$44M
Net Income	$113M	$78M	$125M	$91M	$110M	$117M	$154M	$116M
Net Margin	20.3%	13.1%	18.4%	14.1%	17.4%	17.7%	21.5%	16.7%
EPS (Diluted)	$0.54	$0.37	$0.60	$0.44	$0.53	$0.56	$0.74	$0.56
EBITDA	$210M	$173M	$242M	$195M	$219M	$231M	$285M	$256M
Shares Outstanding	209M	209M	209M	209M	209M	209M	209M	208M

RCDTF OTC